Switch theme
Sign up to access all valuation multiples
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
1970
75K+
LTM Revenue $64.5B
LTM EBITDA $27.5B
$217B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Merck & Co has a last 12-month revenue of $64.5B and a last 12-month EBITDA of $27.5B.
In the most recent fiscal year, Merck & Co achieved revenue of $64.2B and an EBITDA of $25.7B.
Merck & Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Merck & Co valuation multiples based on analyst estimates| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | $64.5B | XXX | XXX | XXX | XXX |
| Gross Profit | $52.5B | XXX | XXX | XXX | XXX |
| Gross Margin | 81% | XXX | XXX | XXX | XXX |
| EBITDA | $27.5B | XXX | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | XXX | XXX | XXX |
| EBIT | $24.8B | XXX | XXX | XXX | XXX |
| EBIT Margin | 38% | XXX | XXX | XXX | XXX |
| Net Profit | $20.7B | XXX | XXX | XXX | XXX |
| Net Margin | 32% | XXX | XXX | XXX | XXX |
| Net Debt | $23.9B | XXX | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Merck & Co's stock price is $76.
Merck & Co has current market cap of $192B, and EV of $217B.
See Merck & Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $217B | $192B | XXX | XXX | XXX | XXX | $8.17 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Merck & Co has market cap of $192B and EV of $217B.
Merck & Co's trades at 3.4x EV/LTM Revenue multiple, and 7.9x EV/LTM EBITDA.
Equity research analysts estimate Merck & Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Merck & Co has a P/E ratio of 9.3x.
See valuation multiples for Merck & Co and 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Market cap (current) | $192B | XXX | XXX | XXX | XXX |
| EV (current) | $217B | XXX | XXX | XXX | XXX |
| EV/Revenue | 3.4x | XXX | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | XXX | XXX | XXX |
| EV/EBIT | 8.8x | XXX | XXX | XXX | XXX |
| EV/Gross Profit | 4.1x | XXX | XXX | XXX | XXX |
| P/E | 9.3x | XXX | XXX | XXX | XXX |
| EV/FCF | 10.9x | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMerck & Co's last 12 month revenue growth is 3%
Merck & Co's revenue per employee for the last 12 months averaged $0.9M, while opex per employee averaged $0.4M for the same period.
Merck & Co's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Merck & Co's rule of X is 50% (another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Merck & Co and other 10K+ public comps| LTM | NTM | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 43% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 13% | XXX | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | XXX | XXX | XXX |
| Bessemer Rule of X | 50% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.9M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Merck & Co acquired XXX companies to date.
Last acquisition by Merck & Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Merck & Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Merck & Co founded? | Merck & Co was founded in 1970. |
| Where is Merck & Co headquartered? | Merck & Co is headquartered in United States of America. |
| How many employees does Merck & Co have? | As of today, Merck & Co has 75K+ employees. |
| Who is the CEO of Merck & Co? | Merck & Co's CEO is Mr. Robert M. Davis. |
| Is Merck & Co publicy listed? | Yes, Merck & Co is a public company listed on NYS. |
| What is the stock symbol of Merck & Co? | Merck & Co trades under MRK ticker. |
| When did Merck & Co go public? | Merck & Co went public in 1949. |
| Who are competitors of Merck & Co? | Similar companies to Merck & Co include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Merck & Co? | Merck & Co's current market cap is $192B |
| What is the current revenue of Merck & Co? | Merck & Co's last 12 months revenue is $64.5B. |
| What is the current revenue growth of Merck & Co? | Merck & Co revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Merck & Co? | Current revenue multiple of Merck & Co is 3.4x. |
| Is Merck & Co profitable? | Yes, Merck & Co is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Merck & Co? | Merck & Co's last 12 months EBITDA is $27.5B. |
| What is Merck & Co's EBITDA margin? | Merck & Co's last 12 months EBITDA margin is 43%. |
| What is the current EV/EBITDA multiple of Merck & Co? | Current EBITDA multiple of Merck & Co is 7.9x. |
| What is the current FCF of Merck & Co? | Merck & Co's last 12 months FCF is $20.0B. |
| What is Merck & Co's FCF margin? | Merck & Co's last 12 months FCF margin is 31%. |
| What is the current EV/FCF multiple of Merck & Co? | Current FCF multiple of Merck & Co is 10.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
